Pancreatic β-Cell production of CXCR3 ligands precedes diabetes onset

BioFactors

Volumn 42, Issue 6, 2016, Pages 703-715

  Burke, Susan J ^a   Karlstad, Michael D ^b   Eder, Adrianna E ^b   Regal, Kellie M ^b   Lu, Danhong ^c   Burk, David H ^a   Collier, J Jason ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^b UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

autoimmunity; chemokine; diabetes; inflammation; islets; transcription

Indexed keywords

CHEMOKINE RECEPTOR CXCR3; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1BETA; STAT1 PROTEIN; STREPTOZOCIN; CXCL11 PROTEIN, MOUSE; CXCL9 PROTEIN, MOUSE; CXCR3 PROTEIN, MOUSE; GLUCOSE BLOOD LEVEL; JANUS KINASE; LIGAND; STAT1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE DELETION; HUMAN; INFLAMMATION; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL LINE; DISEASE COURSE; EXPERIMENTAL DIABETES MELLITUS; GENETICS; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; METABOLISM; NONOBESE DIABETIC MOUSE; PHYSIOLOGY; TRANSCRIPTION INITIATION;

ANIMALS; BLOOD GLUCOSE; CELL LINE; CHEMOKINE CXCL11; CHEMOKINE CXCL9; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; FEMALE; HUMANS; HYPERGLYCEMIA; INSULIN-SECRETING CELLS; JANUS KINASES; LIGANDS; MALE; MICE, INBRED BALB C; MICE, INBRED NOD; PROMOTER REGIONS, GENETIC; RATS; RECEPTORS, CXCR3; STAT1 TRANSCRIPTION FACTOR; TRANSCRIPTIONAL ACTIVATION;

EID: 84976865359     PISSN: 09516433     EISSN: 18728081     Source Type: Journal    
DOI: 10.1002/biof.1304     Document Type: Article

References (55)

1. Meier, J. J. (2008) Beta cell mass in diabetes: a realistic therapeutic target? Diabetologia 51, 703–713.
2. Tuomi, T., Santoro, N., Caprio, S., Cai, M., Weng, J., et al. (2014) The many faces of diabetes: a disease with increasing heterogeneity. Lancet 383, 1084–1094.
3. von Herrath, M. G., and Oldstone, M. B. (1997) Interferon-gamma is essential for destruction of beta cells and development of insulin-dependent diabetes mellitus. J Exp Med 185, 531–539.
4. Arnush, M., Heitmeier, M. R., Scarim, A. L., Marino, M. H., Manning, P. T., et al. (1998) IL-1 produced and released endogenously within human islets inhibits beta cell function. J Clin Invest, 102, 516–526.
5. Sarkar, S. A., Lee, C. E., Victorino, F., Nguyen, T. T., Walters, J. A., et al. (2012) Expression and regulation of chemokines in murine and human type 1 diabetes. Diabetes 61, 436–446.
6. Burke, S. J. and Collier, J. J. (2014) Insulitis and Diabetes: A Perspective on Islet Inflammation. Immunome Research 10:Special Issue: Cytokine Biology.
7. Burke, S. J., and Collier, J. J. (2015) Transcriptional Regulation of Chemokine Genes: A Link to Pancreatic Islet Inflammation? Biomolecules 5, 1020–1034.
8. Baggiolini, M. (1998) Chemokines and leukocyte traffic. Nature 392, 565–568.
9. Karin, N., Wildbaum, G., and Thelen, M. (2015) Biased signaling pathways via CXCR3 control the development and function of CD4+ T cell subsets. J Leukoc Biol.
10. Gerard, C. and Rollins, B. J. (2001) Chemokines and disease. Nat Immunol 2, 108–115.
11. Merani, S., Truong, W. W., Hancock, W., Anderson, C. C., and Shapiro, A. M. (2006) Chemokines and their receptors in islet allograft rejection and as targets for tolerance induction. Cell Transplant 15, 295–309.
12. Castano, L., and Eisenbarth, G. S. (1990) Type-I diabetes: a chronic autoimmune disease of human, mouse, and rat. Annu Rev Immunol 8, 647–679.
13. Laron, Z., Hampe, C. S., and Shulman, L. M. (2015) The urgent need to prevent type 1 autoimmune childhood diabetes. Pediatric Endocrinology Reviews: Per 12, 266–282.
14. Driver, J. P., Chen, Y. G., and Mathews, C. E. (2012) Comparative genetics: synergizing human and NOD mouse studies for identifying genetic causation of type 1 diabetes. Rev Diabet Stud 9, 169–187.
15. Jayasimhan, A., Mansour, K. P., and Slattery, R. M. (2014) Advances in our understanding of the pathophysiology of Type 1 diabetes: lessons from the NOD mouse. Clin Sci (Lond) 126, 18.
16. Anderson, M. S. and Bluestone, J. A. (2005) The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 23, 447–485.
17. Herold, K. C., Montag, A. G., and Fitch, F. W. (1987) Treatment with anti-T-lymphocyte antibodies prevents induction of insulitis in mice given multiple doses of streptozocin. Diabetes 36, 796–801.
18. J. R Groom, and A. D. Luster, (2011) CXCR3 in T cell function. Exp Cell Res 317, 620–631.
19. J. R Groom, and A. D. Luster, (2011) CXCR3 ligands: redundant, collaborative and antagonistic functions. Immunol Cell Biol 89, 207–215.
20. Newton, P., O'Boyle, G., Jenkins, Y., Ali, S., and Kirby, J. A. (2009) T cell extravasation: demonstration of synergy between activation of CXCR3 and the T cell receptor. Mol Immunol 47, 485–492.
21. Boraschi, D., Censini, S., and Tagliabue, A. (1984) Interferon-gamma reduces macrophage-suppressive activity by inhibiting prostaglandin E2 release and inducing interleukin 1 production. J Immunol 133, 764–768.
22. Sarvetnick, N., Shizuru, J., Liggitt, D., Martin, L., McIntyre, B., Gregory, A., Parslow, T., and Stewart, T. (1990) Loss of pancreatic islet tolerance induced by beta-cell expression of interferon-gamma. Nature 346, 844–847.
23. Stark, G. R. and Darnell, J. E. Jr. (2012) The JAK-STAT pathway at twenty. Immunity 36, 503–514.
24. Heitmeier, M. R., Scarim, A. L., and Corbett, J. A. (1997) Interferon-gamma increases the sensitivity of islets of Langerhans for inducible nitric-oxide synthase expression induced by interleukin 1. J Biol Chem 272, 13697–13704.
25. Burke, S. J., Goff, M. R., Lu, D., Proud, D., Karlstad, M. D., et al. (2013) Synergistic Expression of the CXCL10 Gene in Response to IL-1beta and IFN-gamma Involves NF-kappaB, Phosphorylation of STAT1 at Tyr701, and Acetylation of Histones H3 and H4. J Immunol 191, 323–336.
26. Burke, S. J., Updegraff, B. L., Bellich, R. M., Goff, M. R., Lu, D., et al. (2013) Regulation of iNOS Gene Transcription by IL-1beta and IFN-gamma Requires a Coactivator Exchange Mechanism. Mol Endocrinol 27, 1724–1742.
27. Levy, D. E., and Darnell, J. E. Jr. (2002) Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3, 651–662.
28. Asfari, M., Janjic, D., Meda, P., Li, G., Halban, P. A., et al. (1992) Establishment of 2-mercaptoethanol-dependent differentiated insulin-secreting cell lines. Endocrinology 130, 167–178.
29. Hohmeier, H. E., Mulder, H., Chen, G., Henkel-Rieger, R., Prentki, M., and Newgard, C. B. (2000) Isolation of INS-1-derived cell lines with robust ATP-sensitive K+ channel-dependent and -independent glucose-stimulated insulin secretion. Diabetes 49, 424–430.
30. Burke, S. J., Karlstad, M. D., Regal, K. M., Sparer, T. E., Lu, D., et al. (2015) CCL20 is elevated during obesity and differentially regulated by NF-kappaB subunits in pancreatic beta-cells. Biochim Biophys Acta 1849, 637–652.
31. Collier, J. J., Fueger, P. T., Hohmeier, H. E., and Newgard, C. B. (2006) Pro- and antiapoptotic proteins regulate apoptosis but do not protect against cytokine-mediated cytotoxicity in rat islets and beta-cell lines. Diabetes 55, 1398–1406.
32. Collier, J. J., Burke, S. J., Eisenhauer, M. E., Lu, D., Sapp, R. C., et al. (2011) Pancreatic beta-Cell Death in Response to Pro-Inflammatory Cytokines Is Distinct from Genuine Apoptosis. PLoS One 6, e22485.
33. Burke, S. J. and Collier, J. J. (2011) The gene encoding cyclooxygenase-2 is regulated by IL-1beta and prostaglandins in 832/13 rat insulinoma cells. Cell Immunol 271, 379–384.
34. Burke, S. J., Collier, J. J., and Scott, D. K. (2009) cAMP prevents glucose-mediated modifications of histone H3 and recruitment of the RNA polymerase II holoenzyme to the L-PK gene promoter. J Mol Biol 392, 578–588.
35. Young, E. F., Hess, P. R., Arnold, L. W., Tisch, R., and Frelinger, J. A. (2009) Islet lymphocyte subsets in male and female NOD mice are qualitatively similar but quantitatively distinct. Autoimmunity 42, 678–691.
36. Wen, Z., Zhong, Z., and Darnell, J. E. Jr. (1995) Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 82, 241–250.
37. Atkinson, M. A., Eisenbarth, G. S., and Michels, A. W. (2014) Type 1 diabetes. Lancet 383, 69–82.
38. Rodriguez-Calvo, T., Suwandi, J. S., Amirian, N., Zapardiel-Gonzalo, J., Anquetil, F., et al. (2015) Heterogeneity and Lobularity of Pancreatic Pathology in Type 1 Diabetes during the Prediabetic Phase. J Histochem Cytochem, 63, 626–636.
39. I., Sandovici, C. M., Hammerle, W. N., Cooper, N. H., Smith, J. L., Tarry-Adkins, et al. (2016) Ageing is associated with molecular signatures of inflammation and type 2 diabetes in rat pancreatic islets. Diabetologia 59, 502–511.
40. Frigerio, S., Junt, T., Lu, B., Gerard, C., Zumsteg, U., et al. (2002) Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis. Nat Med 8, 1414–1420.
41. Islam, S. A. and Luster, A. D. (2012) T cell homing to epithelial barriers in allergic disease. Nat Med 18, 705–715.
42. Kim, S. H., Cleary, M. M., Fox, H. S., Chantry, D., and Sarvetnick, N. (2002) CCR4-bearing T cells participate in autoimmune diabetes. J Clin Invest, 110, 1675–1686.
43. Carvalho-Pinto, C., Garcia, M. I., Gomez, L., Ballesteros, A., Zaballos, A., et al. (2004) Leukocyte attraction through the CCR5 receptor controls progress from insulitis to diabetes in non-obese diabetic mice. Eur J Immunol 34, 548–557.
44. Yamazaki, T., Yang, X. O., Chung, Y., Fukunaga, A., Nurieva, R., et al. (2008) CCR6 regulates the migration of inflammatory and regulatory T cells. J Immunol 181, 8391–8401.
45. Shan, Z., Xu, B., Mikulowska-Mennis, A., and Michie, S. A. (2014) CCR7 directs the recruitment of T cells into inflamed pancreatic islets of nonobese diabetic (NOD) mice. Immunol Res 58, 351–357.
46. Lasch, S., Muller, P., Bayer, M., Pfeilschifter, J. M., Luster, A. D., et al. (2015) Anti-CD3/anti-CXCL10 antibody combination therapy induces a persistent remission of type 1 diabetes in two mouse models. Diabetes.
47. Kantwerk-Funke, G., Burkart, V., and Kolb, H. (1991) Low dose streptozotocin causes stimulation of the immune system and of anti-islet cytotoxicity in mice. Clin Exp Immunol 86, 266–270.
48. Nathan, C. F. (1987) Secretory products of macrophages. J Clin Invest 79, 319–326.
49. Corbett, J. A., Kwon, G., Turk, J., and McDaniel, M. L. (1993) IL-1 beta induces the coexpression of both nitric oxide synthase and cyclooxygenase by islets of Langerhans: activation of cyclooxygenase by nitric oxide. Biochemistry 32, 13767–13770.
50. Burke, S. J., Stadler, K., Lu, D., Gleason, E., Han, A., et al. (2015) IL-1beta reciprocally regulates chemokine and insulin secretion in pancreatic beta-cells via NF-kappaB. Am J Physiol Endocrinol Metab 309, E715–E726.
51. Hu, C., Ding, H., Li, Y., Pearson, J. A., Zhang, X., et al. (2015) NLRP3 deficiency protects from type 1 diabetes through the regulation of chemotaxis into the pancreatic islets. Proc Natl Acad Sci U S A 112, 11318–11323.
52. Zhou, J., Tang, P. C., Qin, L., Gayed, P. M., Li, W., Skokos, E. A., Kyriakides, T. R., Pober, J. S., and Tellides, G. (2010) CXCR3-dependent accumulation and activation of perivascular macrophages is necessary for homeostatic arterial remodeling to hemodynamic stresses. J Exp Med 207, 1951–1966.
53. Yi, Z., Li, L., Garland, A., He, Q., Wang, H., et al. (2012) IFN-gamma receptor deficiency prevents diabetes induction by diabetogenic CD4+, but not CD8+, T cells. Eur J Immunol 42, 2010–2018.
54. Rhode, A., Pauza, M. E., Barral, A. M., Rodrigo, E., Oldstone, M. B., von Herrath, M. G., and Christen, U. (2005) Islet-specific expression of CXCL10 causes spontaneous islet infiltration and accelerates diabetes development. J Immunol 175, 3516–3524.
55. Roep, B. O., Kleijwegt, F. S., van Halteren, A. G., Bonato, V., Boggi, U., et al. (2010) Islet inflammation and CXCL10 in recent-onset type 1 diabetes. Clin Exp Immunol 159, 338–343.